2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

University of Arkansas (Other)
Overall Status
CT.gov ID
Bristol-Myers Squibb (Industry), Altor BioScience (Industry)
Actual Duration (Months)
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will evaluate the ability of Expanded Natural Killer (ENK) cells to treat multiple myeloma when administered as part of a regimen consisting of Elotuzumab and a stem cell transplant. Natural killer cells are a special type of white blood cells that are already present in the body which have the ability to kill myeloma cells. In this study, natural killer cells will be collected and then treated in a laboratory to activate and 'expand' the number of cells to increase the dose and the anti-myeloma activity of the cells before they are transfused back into the subject. Elotuzumab is a protein drug approved by the United States Food and Drug Administration (FDA) for patients with previously treated multiple myeloma and works by activating natural killer cells already present in the body and targeting a protein called SLAMF7 which is present on both natural killer cells and myeloma cells. The investigators hope that administering Elotuzumab in combination with ENK cells will enhance the anti-myeloma activity of the ENK cells.

Condition or DiseaseIntervention/TreatmentPhase
Phase 2

Study Design

Study Type:
Actual Enrollment :
0 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
2015-10: A Phase II Pilot Study of Expanded Natural Killer Cells and Elotuzumab to Eradicate High-Risk Myeloma Post Autologous Stem Cell Transplant
Actual Study Start Date :
Nov 1, 2019
Actual Primary Completion Date :
Jul 8, 2020
Actual Study Completion Date :
Jul 8, 2020

Arms and Interventions

Experimental: Study Treatment

Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26; Melphalan 200 mg/m2 Ivia intravenous infusion on day -3; ASCT on day -2; ENK infusion on day 0; ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22.

Drug: Elotuzumab
Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26
Other Names:
  • Empliciti
  • Drug: Melphalan
    Melphalan 200 mg/m2 Ivia intravenous infusion on day -3

    Procedure: Autologous Stem Cell Transplant (ASCT)
    ASCT on day -2

    Biological: Expanded Natural Killer (ENK) Cells
    ENK cell infusion on day 0

    Drug: ALT-803
    ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22
    Other Names:
  • IL-15 superagonist
  • Outcome Measures

    Primary Outcome Measures

    1. Multiple Myeloma Response [98 days post-ENK infusion (100 days post-ASCT)]

      Response will be measured according to International Myeloma Working Group (IMWG) Criteria

    Secondary Outcome Measures

    1. Adverse Events [within 98 days post-ENK infusion (100 days post-ASCT)]

      Frequency and severity of treatment-related adverse events

    2. Persistence of ENK cells by flow cytometry and/or cytometry by time of flight (CyTOF) [within 98 days post-ENK infusion (100 days post-ASCT)]

    Eligibility Criteria


    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    • Multiple myeloma patients that have completed induction chemotherapy and peripheral blood stem cell collection (PBSC) in preparation for ASCT.

    • Patients must have high-risk disease as defined by Gene Expression Profiling (GEP) 70 risk score of ≥ 0.66 or GEP 80 gene score of ≥ 2.48 or metaphase cytogenetic abnormalities or lactate dehydrogenase (LDH) ≥ 360 U/L (Rule out hemolysis, infection and contact PI for clarification if any doubt).

    • Patients must have failed prior treatment for their multiple myeloma (MM) including a proteasome inhibitor and immunomodulatory drug (so-called 'double refractory'). Patients who have received prior salvage combination chemotherapy after failure of proteasome inhibitor and immunomodulatory drug are eligible (frank relapse at the time of enrollment is not required)

    • Zubrod ≤ 2, unless solely due to symptoms of MM-related (bone) disease.

    • Patients must have a platelet count of ≥ 20,000/μL within 30 days of enrollment, unless lower levels are explained by extensive bone marrow plasmacytosis or extensive prior therapy.

    • Patients must be at least 18 years of age and not older than 75 years of age at the time of registration.

    • must have preserved renal function as defined by a serum creatinine level of ≤ 3 mg/dL within 30 days of registration.

    • Participants must have an ejection fraction by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan ≥ 40% within 90 days prior to registration.

    • Patients must have adequate pulmonary function studies ≥ 50% of predicted on mechanical aspects and diffusion capacity (DLCO) ≥ 50% of predicted within 90 days prior to registration. If the patient is unable to complete pulmonary function tests due to MM-related pain or condition, exception may be granted if the principal investigator documents that the patient is a candidate for high-dose therapy.

    • Patients must have at least 2x106 CD34+ cells/kg stored for transplant. In addition, there will be a 'back-up' available of 2x106 CD34+ cells/kg2x106 CD34+ cells/kg

    • Patients must have signed an Institutional Review Board-approved informed consent and HIPAA authorization form.

    Exclusion Criteria:
    • Prior allo-transplant.

    • Prior auto-transplantation is permitted provided the patient is still presently a transplant candidate and at least 2 months should have passed since last auto-transplant

    • History of poorly-controlled hypertension, diabetes mellitus, or any other serious medical illness or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol or could be considered to be an exclusion criterion deemed by the PI.

    • Patients must not have prior malignancy, except for adequately-treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has not received treatment for one year prior to enrollment. Other cancers will only be acceptable if the patient's life expectancy exceeds three years as determined by the PI.

    • Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy test documented within one week of registration. Women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.

    • The subject may not be positive for HIV I/II or HTLV-I/II.

    Contacts and Locations


    SiteCityStateCountryPostal Code
    1University of Arkansas for Medical SciencesLittle RockArkansasUnited States72205

    Sponsors and Collaborators

    • University of Arkansas
    • Bristol-Myers Squibb
    • Altor BioScience


    • Principal Investigator: Frits van Rhee, MD, PhD, University of Arkansas

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    University of Arkansas
    ClinicalTrials.gov Identifier:
    Other Study ID Numbers:
    • 205009
    First Posted:
    Dec 28, 2016
    Last Update Posted:
    Jul 10, 2020
    Last Verified:
    Jul 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 10, 2020